-
2023-507837-18-00
6
2025-03-06
Male and female patients aged ≥ 18 to ≤ 80 after total gastrectomy.
-
2024-512946-41-00
5
2025-03-05
Menstrual Migraine
-
2024-518343-38-00
5
2025-02-12
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
-
2024-510730-40-00
5
2024-12-12
Hidradenitis Suppurativa
-
2023-508636-61-00
5
2024-10-24
Crohn’s Disease
-
2024-515871-37-00
5
2024-10-24
Moderate to severe systemic lupus erythematosus
-
2022-502605-15-00
4
2024-09-16
Participants with transthyretin amyloid cardiomyopathy (ATTR CM)
-
2023-510258-17-00
4
2024-07-24
Rheumatoid arthritis (RA)
-
2023-508085-15-00
5
2024-05-15
Chronic Obstructive Pulmonary Disease
-
2023-506029-12-00
5
2024-04-03
Migraine
-
2024-518708-29-00
6
2024-03-13
Transthyretin cardiac amyloidosis
-
2022-502442-27-00
5
2024-01-08
Obesity
-
2022-502593-17-00
5
2023-09-19
Locally advanced or metastatic hormone receptor (HR)-positive, human e
-
2022-501176-26-00
5
2023-08-04
Acute Ischemic Stroke and High-Risk Transient Ischemic Attack
-
2022-501024-20-00
5
2023-07-25
ER+/HER2- Early Breast Cancer
-
2022-501608-85-00
5
2023-05-09
Cardiovascular disease (atherosclerotic cardiovascular disease (ASCVD)
-
2024-511370-72-00
4
2023-03-29
Primary Sclerosing Cholangitis
-
2024-512915-33-00
5
2022-12-22
Metastatic Colorectal Cancer
-
2023-505057-40-00
4
2022-12-02
Lung Cancer, Non-Small Cell
-
2023-509029-29-00
5
2022-06-29
Familial Chylomicronemia Syndrome (FCS)
-
2023-508248-23-00
5
2021-11-26
Non-alcoholic steatohepatitis (NASH)
-
2024-510735-21-00
5
2021-11-26
Atherosclerotic cardiovascular disease (ASCVD)
-
2023-510319-20-00
5
2021-10-21
Gastroesophageal Adenocarcinoma (GEA)
-
2023-503990-39-00
5
2021-09-30
Estrogen Receptor-Positive, HER-2 negative Advanced Breast Cancer